1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,810 | 0,845 | 20:16 | |
| 0,810 | 0,845 | 19:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete | 723 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot... ► Artikel lesen | |
| 17.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 12.02. | MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 672 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 10.02. | Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 621 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 02.02. | NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres | 482 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 20.01. | DealFlow Events: NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference | 923 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 13.01. | NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 | 745 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 01.12.25 | NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles | 685 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 26.11.25 | NANOVIRICIDES, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.11.25 | NanoViricides GAAP EPS of -$0.10 | 16 | Seeking Alpha | ||
| 17.11.25 | NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position | 456 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter... ► Artikel lesen | |
| 14.11.25 | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.25 | NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 | 695 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 12.11.25 | NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 720 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement... ► Artikel lesen | |
| 11.11.25 | NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 694 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a... ► Artikel lesen | |
| 10.11.25 | NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo | 721 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of... ► Artikel lesen | |
| 05.11.25 | NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT | 686 | ACCESS Newswire | NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company")... ► Artikel lesen | |
| 03.11.25 | NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd | 607 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 29.10.25 | Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive | 738 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve... ► Artikel lesen | |
| 27.10.25 | NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 | 736 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 17,100 | -1,04 % | Streit mit Bayer beigelegt: Formycon sichert Vermarktungsstart für Aflibercept-Biosimilar FYB203 in Europa+ | Die Vereinbarung ermögliche Formycon die Markteinführung von FYB203 in Europa und wichtigen anderen Schlüsselmärkten ab Mai. Die Formycon AG habe gemeinsam mit ihrem Lizenzpartner Klinge Biopharma eine... ► Artikel lesen | |
| GOMSPACE | 1,402 | +1,01 % | GomSpace beteiligt sich an europäischem Forschungsprogramm für Verteidigungssatelliten | ||
| ONTO INNOVATION | 182,00 | +4,60 % | Onto Innovation stock holds at Stifel on HBM customer win | ||
| NVE | 57,00 | -0,87 % | Dividendenbekanntmachungen (02.02.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACUITY INC US00508Y1029 0,2 USD 0,1687 EUR ALLY FINANCIAL INC US02005N1000 0,3 USD 0,2531 EUR AMERISERV FINANCIAL INC US03074A1025 0... ► Artikel lesen | |
| RIBER | 5,660 | +0,18 % | RIBER: 2025 performance driven by production systems and the rollout of ROSIE | 2025 performance driven by production systems and the rollout of ROSIE Revenues of €40.3 million in line with guidanceOrder book at December 31, 2025: €26.9 million (+24%) Bezons (France), February... ► Artikel lesen | |
| GAUZY | 0,665 | 0,00 % | GAUZY LTD: Gauzy Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | TEL AVIV, Israel, March 20, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on March 17... ► Artikel lesen | |
| ZENTEK | 0,472 | -8,35 % | Zentek Ltd. Receives Favorable Judgment in Long-Standing Litigation | Ontario Superior Court Dismisses Claims Originally Exceeding $6 Million Against Zentek GUELPH, ON / ACCESS Newswire / March 13, 2026 / Zentek Ltd. (TSXV:ZEN)(NASDAQ:ZTEK) ("Zentek" or the "Company")... ► Artikel lesen | |
| SOLESENCE | 0,920 | +10,03 % | Solésence, Inc.: Solésence Reports Third Quarter 2025 Financial Results | Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN)... ► Artikel lesen | |
| DOTZ NANO | 0,021 | +13,51 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| OBDUCAT | 0,004 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| ACACIA RESEARCH | 4,140 | -0,48 % | ACACIA RESEARCH CORP - 10-K, Annual Report | ||
| ADVANCE ZINCTEK | 0,492 | +64,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 16.02.2026 | Das Instrument OYS US68162K1060 OLYMPIC STEEL EQUITY wird cum Kapitalmassnahme gehandelt am 16.02.2026 und ex Kapitalmassnahme am 17.02.2026 The instrument OYS US68162K1060 OLYMPIC STEEL EQUITY is traded... ► Artikel lesen | |
| LAMPETIA | 0,094 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| XTPL | 15,960 | +0,63 % | EQS-News: XTPL S.A.: XTPL sets issue price of series Y shares at PLN 65.00, offering size to reach PLN 19.5 million | Issuer: XTPL S.A.
/ Key word(s): Capital Increase/Financing
XTPL sets issue price of series Y shares at PLN 65.00, offering size to reach PLN 19.5 million
18.03.2026 /... ► Artikel lesen | |
| NANOFORM FINLAND | 0,607 | -4,41 % | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 0,765 Euro und damit -4,97 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.